Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
RH

OTC · RHHBY

Roche Holding AG

Healthcare · Drug Manufacturers - General

$59.18

Down-$1.49 (-2.46%)

Updated Nov 4, 2026, 10:21 AM

SID Score

5.5/10

Composite research score

Smart Money

46/100

Neutral

Market cap
318.73B
P/E ratio
44.08
Dividend yield
2.30%
52-week range
— – —
Volume
150.7K
Avg. volume
1.86M

Price performance · RHHBY

RHHBY price history

1M range · 0 trading sessions · Daily adjusted prices

RHHBY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RHHBY news

The latest Smart Investors Daily articles mentioning RHHBY.

Stock researchCompany · Overview

RHHBY research

Overview

Company profile and research snapshot.

Company profile

ROCHE HOLDING LTD S/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$57.00
Implied upside
—
Analysts
12
RHHBY recent ratings
DateFirmRatingTarget
Sep 23, 2026BERENBERGHold—
Sep 3, 2026JEFFERIESUnderperform—
Aug 24, 2026HSBC GLOBAL INVESTMENT RESEARCHHold—
Aug 10, 2026TD COWENHold—
Jul 27, 2026ROTHSCHILD & CO REDBURNBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 3, 2026

Biophotonics - Global Strategic Business Report 2026: Secure Share of a US$130.6 Billion Market by 2032, Led by Roche, GE Healthcare, Horiba, and IPG Photonics

Dublin, Nov. 03, 2026 (GLOBE NEWSWIRE) -- "Biophotonics - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global biophotonics market was valued at US$66.7 billion in 2025 and is projected to reach US$130.6 billion by 2032, expanding at a compound annual growth rate (CAGR) of 10.1% during the forecast period. The market's strong outlook reflects continued advances in optical imaging, diagnostics, biosensing, medical therapeutics and life sciences re

Yahoo · Nov 2, 2026

Roche Secures FDA Clearance for New cobas eplex Respiratory Panel Detecting Up to 19 Pathogens

Roche (USOTC:RHHBY) has received 510(k) clearance from the US Food and Drug Administration (FDA) for its cobas eplex respiratory pathogen panel 3 (RP3), a diagnostic test designed to detect up to 19 respiratory viruses and bacteria from a single patient sample. The new panel allows laboratories to select from five testing configurations based on local disease prevalence and patient requirements, while delivering results in less than two hours.

AI research layers

Interpretive context generated from the platform’s current data sources.

Roche Holding AG Stock Performance

Roche Holding AG (RHHBY) trades at $59.18 per share with a market capitalization of approximately $318.7 billion, per SID market data. The stock exhibits notably low volatility relative to the broader market, registering a beta of just 0.166, indicating minimal correlation with general equity market movements. This defensive profile aligns with Roche's positioning within the Healthcare sector, where demand tends to remain resilient through economic cycles. Average daily trading volume stands at approximately 1.86 million shares, according to Massive/Polygon data, reflecting moderate liquidity for the ADR listing. The low beta suggests Roche shares have historically moved roughly one-sixth as much as the broader market index, making the stock a characteristic defensive holding. Investors seeking reduced portfolio volatility have historically gravitated toward names with this risk profile, particularly during periods of macroeconomic uncertainty and elevated market turbulence.

Roche Holding AG Valuation Analysis

Roche Holding AG currently trades at a price-to-earnings ratio of 44.08, per SID market data, representing a significant premium relative to the broader Healthcare sector average. The elevated P/E multiple suggests the market is pricing in substantial future earnings growth or reflects temporary earnings compression. However, the negative PEG ratio of -1.44 indicates that consensus forward earnings growth estimates remain negative, raising questions about whether the current valuation premium is justified by fundamentals. The price-to-book ratio stands at 8.80, according to SEC filings, further underscoring the premium valuation. On the income front, Roche offers a dividend yield of approximately 3.09%, providing a meaningful income component that partially offsets the stretched valuation metrics. This yield remains competitive within the large-cap pharmaceutical space and reflects Roche's longstanding commitment to returning capital to shareholders through consistent dividend distributions.

Smart Money Activity for RHHBY

Roche Holding AG registers a composite smart money score of 46 out of 100 with a neutral signal, per SID market data, suggesting limited conviction among sophisticated market participants. Breaking down the components, insider activity scores 12.5 out of 25, reflecting neither aggressive accumulation nor meaningful distribution by corporate insiders. Institutional positioning scores 13.0 out of 25, indicating moderate but not emphatic institutional interest in the name. Dark pool activity registers a comparatively low score of 8.5 out of 25, according to SEC Form 4 filings and 13F institutional filings, suggesting below-average off-exchange block trading activity. Congressional trading activity scores 12 out of 25, showing neutral engagement from members of Congress who have disclosed positions. The overall neutral reading across all four sub-categories indicates that no single category of sophisticated investor is currently establishing outsized directional positions in Roche shares, leaving the stock without a clear smart money catalyst in either direction.

Roche Holding AG Earnings Outlook

Roche Holding AG has demonstrated a consistent pattern of meeting or exceeding analyst expectations across recent quarters, per company earnings reports. In the most recent quarter ending June 2025, Roche reported earnings of 11.10 versus a consensus estimate of 10.94, delivering a positive surprise of 0.16. The December 2024 quarter similarly produced a beat, with actual earnings of 8.57 exceeding the 8.48 estimate. The strongest outperformance occurred in June 2024, when Roche posted earnings of 10.23 against expectations of 9.34, representing a positive surprise of 0.89, according to analyst estimates. Only the December 2023 quarter saw a marginal miss of -0.016. The four-quarter trend reveals three consecutive beats, indicating management's ability to deliver operational results ahead of Street forecasts. The seasonal pattern shows meaningfully stronger earnings in mid-year quarters relative to year-end periods, consistent with Roche's product cycle and revenue recognition timing.

Wall Street Analyst Ratings for RHHBY

Wall Street consensus on Roche Holding AG leans cautious, with the majority of recent analyst actions reflecting neutral-to-negative positioning, per Wall Street analyst reports. Among the five most recent ratings, three firms maintain Hold recommendations: Berenberg reiterated Hold in September 2026, TD Cowen maintained Hold in August 2026, and HSBC Global Investment Research downgraded the stock from Buy to Hold in August 2026. Jefferies maintains an Underperform rating, reiterated in September 2026, representing the most bearish coverage among tracked analysts. Rothschild & Co Redburn stands as the lone bullish voice, reiterating a Buy rating in July 2026, according to SID consensus data. The HSBC downgrade from Buy to Hold is particularly notable as the only directional change in the recent period, suggesting deteriorating conviction among previously constructive analysts. The prevailing Hold-heavy distribution indicates the Street views Roche as fairly valued at current levels, with limited near-term catalysts for significant price appreciation.

Featured By